|Articles|March 3, 2017
Frost & Sullivan Reveal Asia as Ideal Trial Destination
Frost & Sullivan have released a whitepaper, with Asia Pacific specialist CRO Novotech, revealing that Asia is becoming an ideal destination for clinical trials.
Advertisement
Frost & Sullivan have released a whitepaper, with Asia Pacific specialist CRO Novotech, revealing that Asia is becoming an ideal destination for clinical trials. The report states that this result is due to vast treatment-naive patient pools, clinical infrastructure and low operational costs.
Read the full report here
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Ensuring Digital Trial Platforms Work for Underserved CommunitiesSeptember 10th 2025
eClinical Technology: Misconceptions, Challenges, and OpportunitiesSeptember 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Investigational PD-L1 x VEGF-A Bispecific Antibody Demonstrates Strong Overall Response Rate in Phase II Small Cell Lung Cancer Trial
2
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
3
eClinical Technology: Misconceptions, Challenges, and Opportunities
4
Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
